Taysha Gene Therapies (TSHA) Change in Accured Expenses (2020 - 2026)

Taysha Gene Therapies has reported Change in Accured Expenses for 7 years, with the latest figure at -$5.1 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 142.31% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 182.28% YoY) and the FY2025 annual result came in at $6.3 million, up 542.58% from the prior year.
• Change in Accured Expenses declined to -$5.1 million in Q1 2026 per TSHA's latest filing, from $2.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.0 million in Q3 2025 and troughed at -$7.7 million in Q2 2022.
• A 5-year average of -$934176.5 and a median of -$747000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 2453.04% in 2023, then jumped 2422.64% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$747000.0 in 2022, then tumbled by 170.01% to -$2.0 million in 2023, then jumped by 105.26% to $106000.0 in 2024, then surged by 2422.64% to $2.7 million in 2025, then tumbled by 292.56% to -$5.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$5.1 million, $2.7 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.